Allogene Therapeutics Shares Face Selling Pressure Amid Key Clinical Catalysts

Shares of the biotechnology firm Allogene Therapeutics experienced a notable decline during the previous trading session. The move lower occurred in the absence of fresh corporate announcements, suggesting investor sentiment continues to be shaped by recent quarterly results and the upcoming timeline for critical clinical trial milestones in the year ahead.

A Sharp Pullback in Trading

In yesterday’s session, Allogene’s stock price dropped by 5.3 percent, closing at $1.44. Trading volume saw a slight decrease to approximately 1.5 million shares. This downward shift interrupts a recent period of recovery; over the preceding two weeks, the equity had advanced by more than 14 percent. The latest retreat points to a cautious stance among market participants.

Financial Position: Strong Liquidity Offsets Quarterly Loss

The market’s movement follows the company’s November quarterly report. For the third quarter of 2025, Allogene Therapeutics posted a net loss of $41.4 million, or $0.19 per share. This result surpassed analyst projections, which had anticipated a larger per-share loss of $0.22.

Should investors sell immediately? Or is it worth buying Allogene Therapeutics?

• Q3 2025 Net Loss: $41.4 million.
• Earnings Per Share: -$0.19, beating estimates.
• Cash and Equivalents: $277.1 million as of September 30, 2025.
• Financial Runway: Funds are expected to support operations into the second half of 2027.

The company maintains a solid financial foundation with $277.1 million in cash and equivalents. Management has reiterated that these reserves are projected to fund its ambitious clinical development pipeline through at least the latter part of 2027.

Focus Shifts to Pivotal 2026 Clinical Data Readouts

Investor attention is now firmly fixed on the progress of Allogene’s clinical programs. Three key studies are poised to deliver significant updates:

• ALPHA3 Trial (Cema-cel): This pivotal Phase 2 study, evaluating the therapy as a first-line consolidation treatment for large B-cell lymphoma, continues to advance. An interim efficacy analysis is scheduled for the first half of 2026.
• RESOLUTION Trial (ALLO-329): Patient enrollment for this Phase 1 study in autoimmune diseases commenced in Q2 2025. Initial clinical data from the trial is expected in H1 2026.
• TRAVERSE Trial (ALLO-316): Recruitment for a cohort in this Phase 1b study for renal cell carcinoma has been completed. Data presented at the ASCO 2025 conference indicated early signs of both therapeutic activity and a manageable safety profile.

The next twelve months will be critical in determining whether clinical results from these programs can overcome the current market hesitancy and shift the narrative for Allogene Therapeutics.